The patient was managed with steroids and temporary ICI discontinuation.30 Only one out of four patients with SLE identified in a retrospective study had a mild flare.17 In a retrospective study on patients with cancer and PAD who received a PD-(L)1 inhibitor one patient with SLE was identified.18 The patient experienced cutaneous and joint flare after ICI initiation, managed with topical corticosteroids, prednisone, and temporary anti-PDL-1 discontinuation. The gene discussed is CD274; the disease is systemic lupus erythematosus.